BEZAFIBRATE: 305 Adverse Event Reports & Safety Profile
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
305
Total FAERS Reports
11 (3.6%)
Deaths Reported
132
Hospitalizations
305
As Primary/Secondary Suspect
29
Life-Threatening
18
Disabilities
First Report: 1999 · Latest Report: 20250420
What Are the Most Common BEZAFIBRATE Side Effects?
#1 Most Reported
Myalgia
29 reports (9.5%)
#2 Most Reported
Abdominal pain
25 reports (8.2%)
#3 Most Reported
Rhabdomyolysis
21 reports (6.9%)
All BEZAFIBRATE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Myalgia | 29 | 9.5% | 0 | 6 |
| Abdominal pain | 25 | 8.2% | 0 | 10 |
| Rhabdomyolysis | 21 | 6.9% | 0 | 17 |
| Back pain | 20 | 6.6% | 0 | 4 |
| Blood creatine phosphokinase increased | 19 | 6.2% | 0 | 5 |
| Acute myocardial infarction | 17 | 5.6% | 0 | 3 |
| Pancreatitis acute | 17 | 5.6% | 0 | 17 |
| Pyrexia | 16 | 5.3% | 0 | 2 |
| Acute coronary syndrome | 15 | 4.9% | 0 | 1 |
| Drug intolerance | 15 | 4.9% | 0 | 0 |
| Hypertension | 15 | 4.9% | 0 | 1 |
| Off label use | 15 | 4.9% | 1 | 2 |
| Pulmonary embolism | 15 | 4.9% | 1 | 15 |
| Arthralgia | 14 | 4.6% | 1 | 2 |
| Carotid arteriosclerosis | 14 | 4.6% | 0 | 0 |
| Coronary artery occlusion | 14 | 4.6% | 0 | 1 |
| Coronary artery thrombosis | 14 | 4.6% | 0 | 0 |
| Diarrhoea | 14 | 4.6% | 0 | 10 |
| Diverticular perforation | 14 | 4.6% | 0 | 0 |
| Dyspnoea | 14 | 4.6% | 0 | 0 |
Who Reports BEZAFIBRATE Side Effects? Age & Gender Data
Gender: 41.5% female, 58.5% male. Average age: 61.3 years. Most reports from: JP. View detailed demographics →
Is BEZAFIBRATE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2000 | 1 | 0 | 0 |
| 2001 | 1 | 0 | 0 |
| 2007 | 1 | 0 | 0 |
| 2009 | 1 | 0 | 1 |
| 2010 | 12 | 0 | 4 |
| 2011 | 21 | 0 | 7 |
| 2013 | 7 | 0 | 4 |
| 2014 | 7 | 0 | 4 |
| 2015 | 7 | 1 | 5 |
| 2016 | 13 | 2 | 10 |
| 2017 | 11 | 0 | 9 |
| 2018 | 15 | 1 | 5 |
| 2019 | 28 | 1 | 12 |
| 2020 | 21 | 1 | 14 |
| 2021 | 18 | 0 | 14 |
| 2022 | 8 | 0 | 1 |
| 2023 | 4 | 0 | 3 |
| 2024 | 13 | 0 | 8 |
| 2025 | 1 | 0 | 1 |
What Is BEZAFIBRATE Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 97 |
| Dyslipidaemia | 44 |
| Hyperlipidaemia | 35 |
| Hypercholesterolaemia | 26 |
| Blood cholesterol increased | 13 |
| Primary biliary cholangitis | 13 |
| Blood cholesterol | 7 |
| Cholangitis | 6 |
| Cholangitis sclerosing | 6 |
| Type iia hyperlipidaemia | 6 |
BEZAFIBRATE vs Alternatives: Which Is Safer?
BEZAFIBRATE vs BEZLOTOXUMAB
BEZAFIBRATE vs BGB-11417
BEZAFIBRATE vs BICALUTAMIDE
BEZAFIBRATE vs BICTEGRAVIR
BEZAFIBRATE vs BICTEGRAVIR\EMTRICITABINE\TENOFOVIR ALAFENAMIDE
BEZAFIBRATE vs BIFIDOBACTERIUM LONGUM
BEZAFIBRATE vs BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS
BEZAFIBRATE vs BILASTINE
BEZAFIBRATE vs BIMATOPROST
BEZAFIBRATE vs BIMATOPROST\TIMOLOL
Official FDA Label for BEZAFIBRATE
Official prescribing information from the FDA-approved drug label.